Cryoport, Inc. (NASDAQ:CYRX) Shares Purchased by Clearbridge Investments LLC

Clearbridge Investments LLC boosted its position in shares of Cryoport, Inc. (NASDAQ:CYRX) by 2.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,257,670 shares of the company’s stock after purchasing an additional 32,496 shares during the period. Clearbridge Investments LLC owned approximately 2.76% of Cryoport worth $30,184,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. UBS Group AG lifted its holdings in Cryoport by 18.8% in the first quarter. UBS Group AG now owns 184,486 shares of the company’s stock valued at $4,428,000 after acquiring an additional 29,157 shares during the last quarter. First Republic Investment Management Inc. raised its position in Cryoport by 4.0% in the first quarter. First Republic Investment Management Inc. now owns 26,030 shares of the company’s stock valued at $625,000 after purchasing an additional 1,012 shares during the period. FMR LLC lifted its stake in shares of Cryoport by 34.1% in the 1st quarter. FMR LLC now owns 2,935 shares of the company’s stock valued at $70,000 after purchasing an additional 747 shares during the last quarter. Envestnet Asset Management Inc. grew its holdings in shares of Cryoport by 194.0% during the 1st quarter. Envestnet Asset Management Inc. now owns 185,681 shares of the company’s stock worth $1,348,000 after purchasing an additional 122,520 shares during the period. Finally, Rhumbline Advisers increased its position in shares of Cryoport by 3.1% during the 1st quarter. Rhumbline Advisers now owns 61,449 shares of the company’s stock worth $1,475,000 after purchasing an additional 1,826 shares during the last quarter. 92.90% of the stock is currently owned by institutional investors and hedge funds.

Cryoport Stock Performance

Cryoport stock opened at $14.19 on Tuesday. The stock’s fifty day simple moving average is $15.34 and its 200-day simple moving average is $19.04. Cryoport, Inc. has a twelve month low of $12.39 and a twelve month high of $34.94. The company has a quick ratio of 13.82, a current ratio of 14.54 and a debt-to-equity ratio of 0.78.

Cryoport (NASDAQ:CYRX) last issued its quarterly earnings results on Wednesday, August 9th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.17). The company had revenue of $57.02 million for the quarter, compared to analysts’ expectations of $56.94 million. Cryoport had a negative return on equity of 7.23% and a negative net margin of 16.07%. On average, analysts expect that Cryoport, Inc. will post -1.07 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have weighed in on CYRX shares. SVB Securities lowered shares of Cryoport from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $30.00 to $10.00 in a research note on Thursday, July 13th. B. Riley lowered their price objective on shares of Cryoport from $30.00 to $22.00 in a research report on Thursday, July 13th. SVB Leerink lowered Cryoport from an “outperform” rating to a “market perform” rating in a research report on Thursday, July 13th. Needham & Company LLC decreased their price target on Cryoport from $30.00 to $21.00 and set a “buy” rating on the stock in a research note on Thursday, August 10th. Finally, Stephens cut Cryoport from an “overweight” rating to an “equal weight” rating and set a $15.00 price objective for the company. in a research note on Thursday, August 10th. Five analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, Cryoport has a consensus rating of “Hold” and a consensus price target of $20.78.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments: Global Logistics Solutions and Global Bioservices. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.